NEW YORK (GenomeWeb News) – Rosetta Genomics' stock soared 72 percent in mid-afternoon trading on Nasdaq after announcing a successful clinical study on one of its lung cancer diagnostic tests.
The Rehovot, Israel-based company's share price rose $1.33 to $3.18 from yesterday's close of $1.85.
A joint study by the company and Johns Hopkins University showed that the firm's miRview squamous non-small cell lung cancer diagnostic accurately classified NSCLC samples from resection and from fine-needle aspirate cell blocks, Rosetta said.
The miRview test, offered in the US by Prometheus Laboratories under the brand name ProOnc, is a microRNA-based molecular assay that classifies NSCLCs using the expression level of a single microRNA biomarker.
Details of the research are set to be published in the January 15 issue of the American Association for Cancer Research’s journal Clinical Cancer Research.
Rosetta Genomics' CEO, Ken Berlin, said in a statement that the study validated the miRview test's "sensitivity, specificity, reproducibility, and overall reliability in helping physicians accurately make this critical lung cancer classification."